212 related articles for article (PubMed ID: 31644262)
1. Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.
Li X; Shao F; Sun J; Du K; Sun Y; Feng F
ACS Appl Mater Interfaces; 2019 Nov; 11(45):41935-41945. PubMed ID: 31644262
[TBL] [Abstract][Full Text] [Related]
2. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.
Du K; Xia Q; Sun J; Feng F
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55851-55861. PubMed ID: 34788006
[TBL] [Abstract][Full Text] [Related]
3. Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy against Glioblastoma Multiforme.
Wang X; Hu A; Du K; Feng F
ACS Appl Bio Mater; 2021 Nov; 4(11):8004-8012. PubMed ID: 35006781
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.
Du K; Xia Q; Heng H; Feng F
ACS Appl Mater Interfaces; 2020 Aug; 12(31):34599-34609. PubMed ID: 32648735
[TBL] [Abstract][Full Text] [Related]
5. Polymer-Drug Conjugates Codeliver a Temozolomide Intermediate and Nitric Oxide for Enhanced Chemotherapy against Glioblastoma Multiforme.
Du K; Li X; Feng F
ACS Appl Bio Mater; 2024 Mar; 7(3):1810-1819. PubMed ID: 38403964
[TBL] [Abstract][Full Text] [Related]
6. Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage.
Bouzinab K; Summers HS; Stevens MFG; Moody CJ; Thomas NR; Gershkovich P; Weston N; Ashford MB; Bradshaw TD; Turyanska L
ACS Appl Mater Interfaces; 2020 Mar; 12(11):12609-12617. PubMed ID: 32073826
[TBL] [Abstract][Full Text] [Related]
7. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
8. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy.
Ramalho MJ; Andrade S; Coelho MÁN; Loureiro JA; Pereira MC
Eur J Pharm Biopharm; 2019 Mar; 136():156-163. PubMed ID: 30682492
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide resistance in glioblastoma multiforme.
Lee SY
Genes Dis; 2016 Sep; 3(3):198-210. PubMed ID: 30258889
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.
Petrenko D; Chubarev V; Syzrantsev N; Ismail N; Merkulov V; Sologova S; Grigorevskikh E; Smolyarchuk E; Alyautdin R
Molecules; 2022 May; 27(11):. PubMed ID: 35684445
[TBL] [Abstract][Full Text] [Related]
11. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
12. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers.
Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M
Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide nanoparticles for targeted glioblastoma therapy.
Fang C; Wang K; Stephen ZR; Mu Q; Kievit FM; Chiu DT; Press OW; Zhang M
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6674-82. PubMed ID: 25751368
[TBL] [Abstract][Full Text] [Related]
14. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
15. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells.
Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G
ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470
[TBL] [Abstract][Full Text] [Related]
16. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma.
Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S
Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370
[TBL] [Abstract][Full Text] [Related]
18. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Efficacy of Temozolomide Loaded by a Tetrahedral Framework DNA Nanoparticle in the Therapy for Glioblastoma.
Fu W; You C; Ma L; Li H; Ju Y; Guo X; Shi S; Zhang T; Zhou R; Lin Y
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39525-39533. PubMed ID: 31601097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
